Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 27: Line 27:
  
 
=Approved antineoplastics=
 
=Approved antineoplastics=
−
''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). This includes drugs that are no longer on the market, which are labeled as '''discontinued'''. Biosimilars are also indexed here, indented below their parent compound.''
+
''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.''
 
==A==
 
==A==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
Line 50: Line 50:
 
*[[Amifostine (Ethyol)]]
 
*[[Amifostine (Ethyol)]]
 
*[[Aminoglutethimide (Cytadren)]]
 
*[[Aminoglutethimide (Cytadren)]]
−
*[[Aminopterin]] '''discontinued'''
 
 
*[[Amivantamab (Rybrevant)]] '''FDA approved 5/21/2021'''
 
*[[Amivantamab (Rybrevant)]] '''FDA approved 5/21/2021'''
 
*[[Amrubicin (Calsed)]]
 
*[[Amrubicin (Calsed)]]
Line 60: Line 59:
 
*[[Arsenic trioxide (Trisenox)]]
 
*[[Arsenic trioxide (Trisenox)]]
 
*[[Asciminib (Scemblix)]] '''FDA approved 10/29/2021'''
 
*[[Asciminib (Scemblix)]] '''FDA approved 10/29/2021'''
−
*[[Asparaginase (Elspar)]] '''discontinued'''
 
 
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]]
 
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]]
 
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] '''FDA approved 6/30/2021'''
 
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] '''FDA approved 6/30/2021'''
Line 158: Line 156:
 
*[[Dasatinib (Sprycel)]]
 
*[[Dasatinib (Sprycel)]]
 
*[[Daunorubicin (Cerubidine)]]
 
*[[Daunorubicin (Cerubidine)]]
−
*[[Daunorubicin liposomal (DaunoXome)]]
 
 
*[[Decitabine (Dacogen)]]
 
*[[Decitabine (Dacogen)]]
 
*[[Decitabine and cedazuridine (Inqovi)]]
 
*[[Decitabine and cedazuridine (Inqovi)]]
 
*[[Degarelix (Firmagon)]]
 
*[[Degarelix (Firmagon)]]
−
*[[Denileukin diftitox (Ontak)]]
 
 
*[[Dexamethasone (Decadron)]]
 
*[[Dexamethasone (Decadron)]]
−
*[[Diethylstilbestrol (DES)]]
 
 
*[[Dinutuximab (Unituxin)]]
 
*[[Dinutuximab (Unituxin)]]
 
*[[Docetaxel (Taxotere)]]
 
*[[Docetaxel (Taxotere)]]
Line 181: Line 176:
 
|}
 
|}
  
−
*[[Edrecolomab (Panorex)]] '''discontinued'''
 
 
*[[Elotuzumab (Empliciti)]]
 
*[[Elotuzumab (Empliciti)]]
 
*[[Emapalumab (Gamifant)]]
 
*[[Emapalumab (Gamifant)]]
Line 204: Line 198:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
−
 
 
*[[Fam-trastuzumab deruxtecan (Enhertu)]]
 
*[[Fam-trastuzumab deruxtecan (Enhertu)]]
 
*[[Fedratinib (Inrebic)]]
 
*[[Fedratinib (Inrebic)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
−
*[[Floxuridine (FUDR)]]
 
 
*[[Fludarabine (Fludara)]]
 
*[[Fludarabine (Fludara)]]
−
*[[Fluoxymesterone (Halotestin)]]
 
 
*[[Flutamide (Eulexin)]]
 
*[[Flutamide (Eulexin)]]
 
*[[Folinic acid (Leucovorin)]]
 
*[[Folinic acid (Leucovorin)]]
−
*[[Formestane (Lentaron)]]
 
 
*[[Fostamatinib (Tavalisse)]]
 
*[[Fostamatinib (Tavalisse)]]
 
*[[Fulvestrant (Faslodex)]]
 
*[[Fulvestrant (Faslodex)]]
Line 291: Line 281:
 
*[[Letrozole (Femara)]]
 
*[[Letrozole (Femara)]]
 
*[[Leuprolide (Lupron)]]
 
*[[Leuprolide (Lupron)]]
−
*[[Levamisole (Ergamisol)]] '''discontinued'''
 
 
*[[Levoleucovorin (Fusilev)]]
 
*[[Levoleucovorin (Fusilev)]]
 
*[[Lisocabtagene maraleucel (Breyanzi)]] '''FDA approved 2/5/2021'''
 
*[[Lisocabtagene maraleucel (Breyanzi)]] '''FDA approved 2/5/2021'''
Line 311: Line 300:
 
*[[Megestrol (Megace)]]
 
*[[Megestrol (Megace)]]
 
*[[Melphalan (Alkeran)]]
 
*[[Melphalan (Alkeran)]]
−
*[[Melphalan flufenamide (Pepaxto)]] '''discontinued'''
 
 
*[[Mepolizumab (Nucala)]]
 
*[[Mepolizumab (Nucala)]]
 
*[[Mercaptopurine (6-MP)]]
 
*[[Mercaptopurine (6-MP)]]
Line 357: Line 345:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
−
 
 
*[[Obinutuzumab (Gazyva)]]
 
*[[Obinutuzumab (Gazyva)]]
 
*[[Octreotide (Sandostatin)]]
 
*[[Octreotide (Sandostatin)]]
Line 363: Line 350:
 
*[[Ofatumumab (Arzerra)]]
 
*[[Ofatumumab (Arzerra)]]
 
*[[Olaparib (Lynparza)]]
 
*[[Olaparib (Lynparza)]]
−
*[[Olaratumab (Lartruvo)]] '''discontinued'''
 
 
*[[Omacetaxine (Synribo)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Osimertinib (Tagrisso)]]
 
*[[Osimertinib (Tagrisso)]]
Line 393: Line 379:
 
*[[Pirarubicin (THP)]]
 
*[[Pirarubicin (THP)]]
 
*[[Pixantrone (Pixuvri)]]
 
*[[Pixantrone (Pixuvri)]]
−
*[[Plicamycin (Mithracin)]]
 
 
*[[Polatuzumab vedotin (Polivy)]]
 
*[[Polatuzumab vedotin (Polivy)]]
 
*[[Pomalidomide (Pomalyst)]]
 
*[[Pomalidomide (Pomalyst)]]
Line 445: Line 430:
 
*[[Selpercatinib (Retevmo)]]
 
*[[Selpercatinib (Retevmo)]]
 
*[[Selumetinib (Koselugo)]]
 
*[[Selumetinib (Koselugo)]]
−
*[[Semustine (MeCCNU)]]
 
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sirolimus protein-bound particles (Fyarro)]] '''FDA approved 11/22/2021'''
 
*[[Sirolimus protein-bound particles (Fyarro)]] '''FDA approved 11/22/2021'''
Line 476: Line 460:
 
*[[Teniposide (Vumon)]]
 
*[[Teniposide (Vumon)]]
 
*[[Tepotinib (Tepmetko)]] '''FDA approved 2/3/2021'''
 
*[[Tepotinib (Tepmetko)]] '''FDA approved 2/3/2021'''
−
*[[Testolactone (Teslac)]] '''discontinued'''
 
 
*[[Thalidomide (Thalomid)]]
 
*[[Thalidomide (Thalomid)]]
 
*[[Thioguanine (Tabloid)]]
 
*[[Thioguanine (Tabloid)]]
Line 509: Line 492:
 
|}
 
|}
 
*[[Umbralisib (Ukoniq)]] '''FDA approved 2/5/2021'''
 
*[[Umbralisib (Ukoniq)]] '''FDA approved 2/5/2021'''
−
*[[Uracil mustard]]
 
−
*[[Urethane]]
 
  
 
==V==
 
==V==
Line 538: Line 519:
 
*[[Zanubrutinib (Brukinsa)]]
 
*[[Zanubrutinib (Brukinsa)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 +
 +
=Discontinued antineoplastics=
 +
''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.
 +
 +
==A==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Aminopterin]]
 +
*[[Asparaginase (Elspar)]]
 +
 +
==D==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Daunorubicin liposomal (DaunoXome)]]
 +
*[[Denileukin diftitox (Ontak)]]
 +
*[[Diethylstilbestrol (DES)]]
 +
 +
==E==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Edrecolomab (Panorex)]]
 +
 +
==F==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Floxuridine (FUDR)]]
 +
*[[Fluoxymesterone (Halotestin)]]
 +
*[[Formestane (Lentaron)]]
 +
 +
==L==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Levamisole (Ergamisol)]]
 +
 +
==M==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Melphalan flufenamide (Pepaxto)]]
 +
 +
==O==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Olaratumab (Lartruvo)]]
 +
 +
==P==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Plicamycin (Mithracin)]]
 +
 +
==S==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Semustine (MeCCNU)]]
 +
 +
==T==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Testolactone (Teslac)]]
 +
 +
==U==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
*[[Uracil mustard]]
 +
*[[Urethane]]
  
 
=Investigational antineoplastics=
 
=Investigational antineoplastics=

Revision as of 14:01, 21 March 2022

Guidelines

back to top

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Older

Antimicrobials

Growth factors

Approved antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

R

back to top

S

back to top

T

back to top

U

back to top

V

back to top

Z

back to top

Discontinued antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.

A

back to top

D

back to top

E

back to top

F

back to top

L

back to top

M

back to top

O

back to top

P

back to top

S

back to top

T

back to top

U

back to top

Investigational antineoplastics

This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

L

back to top

M

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

back to top

V

back to top

Z

back to top

Supportive and other medications

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Condition

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=55305"